Speaker Profile
Elisabeth M. Zeisberg

Elisabeth M. Zeisberg MD

Pulmonology, Cardiology
Gottingen, Gottingen, Germany

Connect with the speaker?

Dr. Elisabeth Zeisberg endeavors to understand the pathogenesis of cardiac fibrogenesis by linking experimental models to clinical observations. Within this aim she identified endothelial to mesenchymal transition (EndMT) as a new mechanism which contributes to fibrosis (Nat Med 2007). Based on the finding that EndMT and fibrogenesis is driven by epigenetic silencing of fibrosis-suppressor genes via aberrant DNA methylation (Nat Med 2010), the Zeisberg team was one of the first to demonstrate gene-specific reversal of such DNA methylation and the first to demonstrate its utility as anti-fibrotic therapy in vivo (Nat Comm 2018).
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)